AR071891A1 - Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) - Google Patents

Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)

Info

Publication number
AR071891A1
AR071891A1 ARP090101855A ARP090101855A AR071891A1 AR 071891 A1 AR071891 A1 AR 071891A1 AR P090101855 A ARP090101855 A AR P090101855A AR P090101855 A ARP090101855 A AR P090101855A AR 071891 A1 AR071891 A1 AR 071891A1
Authority
AR
Argentina
Prior art keywords
seq
sequence
antibody
thirosine
kinase
Prior art date
Application number
ARP090101855A
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41092183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of AR071891A1 publication Critical patent/AR071891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Adem s proporciona metodos para tratar leucemia al administrar una cantidad efectiva de un anticuerpo ya sea solo o en combinacion con un agente anti-c ncer o tratamiento que incluye metotrexato. Reivindicacion 1: Un anticuerpo que enlaza espec¡ficamente el FLT3 humano (SEQ ID Ns 43), caracterizado porque comprende un CDRH1 que tiene la secuencia SYYMH (SEQ ID Ns 2), un CDRH2 que tiene la secuencia IINPSGGSTSYAQKFQG (SEQ ID Ns 3), un CDRH3 que tiene la secuencia GVGAHDAFDI (SEQ ID Ns 4) o VVAAAVADY (SEQ ID Ns 5), un CDRL1 que tiene la secuencia RSSQSLLHSNGNNYLD (SEQ ID Ns 6) o RSSQSLLHSNGYNYLD (SEQ ID Ns 7), un CDRL2 que tiene la secuencia LGSNRAS (SEQ ID Ns 8), y un CDRL3 que tiene la secuencia MQGTHPAIS (SEQ ID Ns 9) o MQSLQTPFT (SEQ ID Ns 11). Reivindicacion 8: Un  cido polinucleico aislado, caracterizado porque comprende una secuencia de nucleotidos que codifica el anticuerpo o fragmento de conformidad con cualesquiera de las reivindicaciones 1-7. Reivindicacion 12: Una composicion farmaceutica, caracterizada porque comprende un anticuerpo o fragmento de conformidad con las reivindicaciones 1-7 o 11 junto con un portador, diluyente o excipiente farmaceuticamente aceptable.
ARP090101855A 2008-05-30 2009-05-22 Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) AR071891A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13039508P 2008-05-30 2008-05-30
US13039408P 2008-05-30 2008-05-30
US13053908P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
AR071891A1 true AR071891A1 (es) 2010-07-21

Family

ID=41092183

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101855A AR071891A1 (es) 2008-05-30 2009-05-22 Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)

Country Status (18)

Country Link
US (3) US20090297529A1 (es)
EP (1) EP2300500A1 (es)
JP (1) JP2011521647A (es)
KR (1) KR20110004455A (es)
CN (1) CN102046659A (es)
AR (1) AR071891A1 (es)
AU (1) AU2009260517B2 (es)
BR (1) BRPI0912173A2 (es)
CA (1) CA2726522A1 (es)
CL (1) CL2009001277A1 (es)
EA (1) EA201071421A1 (es)
IL (1) IL209142A0 (es)
MX (1) MX2010013144A (es)
NZ (1) NZ588791A (es)
PE (1) PE20091963A1 (es)
TW (1) TWI374032B (es)
WO (1) WO2009155015A1 (es)
ZA (1) ZA201008024B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
US20130156764A1 (en) * 2010-03-12 2013-06-20 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
ES2806146T3 (es) * 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
US20150064203A1 (en) 2012-03-08 2015-03-05 Japan Science And Technology Agency Anticancer agent
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN107614010A (zh) * 2015-03-09 2018-01-19 艾更斯司股份有限公司 结合至flt3蛋白的抗体药物偶联物(adc)
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
EP3569244A1 (en) * 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US11299546B2 (en) * 2016-05-27 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
SG10202108528QA (en) * 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
PE20191846A1 (es) * 2017-06-02 2019-12-31 Pfizer Anticuerpos especificos para flt3 y sus usos
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MA49769A (fr) * 2017-07-31 2021-04-21 Dragonfly Therapeutics Inc Protéines se liant à nkg2d, cd16 et flt3
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
KR20200069358A (ko) 2017-10-25 2020-06-16 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JOP20210151A1 (ar) * 2018-12-18 2023-01-30 Boehringer Ingelheim Io Canada Inc أجسام مضادة ناهضة لـ flt3 واستخداماتها
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
US20220160771A1 (en) * 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
SG11202111130SA (en) * 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
US20240132598A1 (en) * 2019-10-15 2024-04-25 Dragonfly Therapeutics, Inc. Antibodies targeting flt3 and use thereof
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
EP4136114A1 (en) * 2020-04-14 2023-02-22 Les Laboratoires Servier Anti-flt3 antibodies and compositions
IL297236A (en) 2020-04-17 2022-12-01 Hope City Cells modified with a flt3-specific chimeric antigen receptor for the treatment of flt3-positive cancers
US20230174614A1 (en) 2020-04-30 2023-06-08 Terry J FRY Multispecific anti-flt3 chimeric antigen receptors
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN111808821B (zh) * 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2022104061A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
CA3229526A1 (en) * 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3869584D1 (de) 1987-04-03 1992-04-30 Hermann Hofmann Verfahren zum kompostieren von organischen stoffen und vorrichtung zur durchfuehrung dieses verfahrens.
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US7534867B1 (en) * 1993-05-19 2009-05-19 Schering Corporation Purified mammalian Flt3 ligands; agonists; antagonists
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
JPH09502352A (ja) 1993-09-08 1997-03-11 イムクローン システムズ インコーポレイテッド Ｆｌｋ−２レセプターを認識するモノクローナル抗体および原始造血幹細胞集団の単離
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19608769C1 (de) * 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US6084060A (en) 1996-12-09 2000-07-04 Imclone Systems Incorporated Composition and method for preserving progenitor cells
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
US6999122B1 (en) * 1999-07-22 2006-02-14 Minolta Co., Ltd. Solid-state logarithmic image sensing device
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JPWO2005094823A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)

Also Published As

Publication number Publication date
KR20110004455A (ko) 2011-01-13
US20110091470A1 (en) 2011-04-21
TWI374032B (en) 2012-10-11
BRPI0912173A2 (pt) 2016-07-26
CN102046659A (zh) 2011-05-04
CA2726522A1 (en) 2009-12-23
US8071099B2 (en) 2011-12-06
ZA201008024B (en) 2012-04-25
CL2009001277A1 (es) 2010-10-08
JP2011521647A (ja) 2011-07-28
US20110008355A1 (en) 2011-01-13
NZ588791A (en) 2012-05-25
TW201010722A (en) 2010-03-16
EP2300500A1 (en) 2011-03-30
US20090297529A1 (en) 2009-12-03
EA201071421A1 (ru) 2011-08-30
IL209142A0 (en) 2011-01-31
AU2009260517B2 (en) 2012-12-06
AU2009260517A1 (en) 2009-12-23
PE20091963A1 (es) 2010-01-15
WO2009155015A1 (en) 2009-12-23
MX2010013144A (es) 2010-12-21

Similar Documents

Publication Publication Date Title
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
JP2020500538A5 (es)
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
AR073770A1 (es) Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
AR081556A1 (es) Proteinas de union al antigeno humanizadas
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
AR070821A1 (es) Anticuerpo anti- tyrp1 (antitiroxina humana)
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
JP2012510461A5 (es)
JP2015522252A5 (es)
ES2430068T3 (es) Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20091674A1 (es) Antagonistas del receptor de glucagon
HRP20171775T1 (hr) Molekule protutijela koje vežu trombin i njihova uporaba
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
CO2018001256A2 (es) Anticuerpos anti-cd154 y métodos para producir los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal